Last update 15 Jun 2026

SAL-0140

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
SAL 0140, SAL0140
Target
Aldosterone
Action
antagonists
Mechanism
Aldosterone antagonists
Therapeutic Areas
Cardiovascular DiseasesEndocrinology and Metabolic DiseaseUrogenital Diseases
Active Indication
Chronic Kidney DiseasesHyperaldosteronismResistant hypertension
Inactive Indication-
Originator Organization
Shenzhen Salubris Pharmaceuticals Co., Ltd.Shenzhen Salubris Pharmaceuticals Co., Ltd.
Active Organization
Shenzhen Salubris Pharmaceuticals Co., Ltd.Shenzhen Salubris Pharmaceuticals Co., Ltd.
Inactive Organization-
License Organization-
Drug Highest PhasePhase 2
First Approval Date-
Regulation-
Login to view timeline

Related

5
Clinical Trials associated with SAL-0140
NCT07646535
/ Not yet recruitingPhase 2
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Trial of Efficacy and Safety of SAL0140 at Different Doses in Patients With Primary Aldosteronism
CTR20254947
/ CompletedPhase 1
SAL0140片在不同程度肾功能不全患者及匹配的肾功能正常健康试验参与者中的药代动力学研究
[Translation] Pharmacokinetic studies of SAL0140 tablets in patients with varying degrees of renal insufficiency and matched healthy participants with normal renal function.
NCT07051603
/ RecruitingPhase 1
A Phase 1, Randomized, Double-Blind Placebo-Controlled Single and Multiple Dose Study Plus Food Effect Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of SAL0140 in Healthy Chinese Subjects
100 Clinical Results associated with SAL-0140
Login to view more data
100 Translational Medicine associated with SAL-0140
Login to view more data
100 Patents (Medical) associated with SAL-0140
Login to view more data
100 Deals associated with SAL-0140
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Chronic Kidney DiseasesPhase 2
China
Shenzhen Salubris Pharmaceuticals Co., Ltd.Shenzhen Salubris Pharmaceuticals Co., Ltd.
15 Jun 2026
HyperaldosteronismPhase 2
China
Shenzhen Salubris Pharmaceuticals Co., Ltd.Shenzhen Salubris Pharmaceuticals Co., Ltd.
26 May 2026
Resistant hypertensionPhase 2
China
Shenzhen Salubris Pharmaceuticals Co., Ltd.Shenzhen Salubris Pharmaceuticals Co., Ltd.
25 Nov 2025
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free